CTLA4 and non-small cell lung carcinoma: To investigate the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or with low-dose radiotherapy or hypofractionated radiotherapy, in patients with metastatic NSCLC who have progressed on previous PD-L1 therapy.